Researchers at Fred Hutchinson Cancer Center, led by Dr. Julie McElrath, Director of the Vaccine and Infectious Disease Division, have found a new way to train our immune system to make antibodies ...

or RAD51C/D mutations, according to findings from the Phase I/IIa PETRA study. In February 2024, Capivasertib combined with docetaxel to enhance anti-tumour activity through inhibition of AKT ...